NeOnc Technologies Holdings Inc. (NASDAQ: NTHI) appointed David Choi as chief accounting officer, the clinical-stage biopharmaceutical company announced. Choi will oversee accounting, financial reporting, internal controls, and corporate governance functions as the company advances its central nervous system cancer therapies.

Choi brings more than a decade of experience in accounting and financial reporting for public and private companies. He previously served as a director at Blythe Global Advisors, where he advised companies on technical accounting matters, SEC reporting, and SOX compliance. His work included financial reporting transformation, internal control implementation, and accounting for complex transactions involving equity instruments, debt financing, and business combinations.

Earlier in his career, Choi held positions at Grant Thornton and Ernst & Young, providing assurance and advisory services. His experience encompasses financial statement audits, technical accounting advisory, and SOX compliance for internal controls over financial reporting.

"David's extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc," said Amir Heshmatpour, chairman and CEO. "As we accelerate our clinical trials and prepare for the next stages of corporate growth, maintaining rigorous financial controls and governance is essential."

Choi is a certified public accountant and holds a master of professional accountancy and bachelor of arts in business economics with a minor in accounting from the University of California, Irvine.

NeOnc develops therapies for central nervous system cancers and has two drug candidates, NEO100 and NEO212, in Phase II clinical trials. Both therapeutics operate under FDA Fast-Track and Investigational New Drug status. The company's patent portfolio extends to 2038 and was exclusively licensed from the University of Southern California.